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Mesenchymal stem cells (MSCs) are multipotent
stromal cells originated from bone marrow and other
adult tissues. MSCs are capable of differentiating into
adipogenic, osteogenic, and chondrogenic lineages.
Transplantation of bone marrow-derived MSCs has
displayed some promise in the management against
ischemic injuries such as myocardial infarction. Aging
exhibited increased vulnerability of MSCs to hypoxic
injury, higher inositol pyrophosphate 7 (IP7) levels,
and decreased Akt phosphorylation. Inhibition of
inositol hexakis phosphate kinases (IP6Ks) activates
Akt signaling, decreases apoptosis, and modulates
paracrine profiles in aged MSCs, and this greatly
enhances the therapeutic efficacy of aged MSCs in
the face of hypoxic injury.stem cells and the tissue environment that surroundsIn this issue of Stem Cell Research & Therapy, Zhang
and colleagues report that the advanced aging process
drastically increases the vulnerability of mesenchymal
stem cells (MSCs) to hypoxic injury [1]. These findings
reveal a tie between pathological conditions such as
aging and compromised MSC transplantation efficacy.
Acute myocardial infarction (AMI) is the leading cause of
morbidity and mortality in developed and developing
countries. Rapid adoption of routine invasive strategies
and intensive pharmacotherapy has been established to
normalize coronary perfusion and enable viable ischemic
tissue to recover from ischemic injury, thus reducing the* Correspondence: jren@uwyo.edu
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2014mortality rate in patients with AMI [2,3]. Nonetheless, a
significant portion of patients with AMI still develop left
ventricular remodeling and heart failure with a subsequent
high risk of mortality [4]. How to effectively restore heart
function among patients with AMI remains a major clin-
ical challenge. Ample clinical and experimental evidence
during the past decades has depicted a role for stem cell
therapy as a rather promising treatment avenue to facili-
tate myocardial function recovery after AMI. In particular,
MSCs have been considered as a candidate for cardiac cell
therapy because of their availability and plasticity [5].
Nonetheless, the poor survival and retention of implanted
MSCs in the injury site because of the existence of a num-
ber of pathological conditions greatly limit the therapeutic
potential of MSC therapy.
A previous study has demonstrated that the aging
process may unfavorably affect the functional activity of
them, thus limiting the therapeutic potential of MSCs [6].
Nonetheless, the mechanism behind decreased viability
and impaired function of the aged engrafted MSCs
remains unclarified. It was well perceived that the aging
process directly affects cell-mediated improvement of
neovascularization, revealing that young, but not old, bone
marrow cells may be more readily incorporated into the
neovasculature to restore cardiac angiogenic function [7].
Liang and colleagues [8] also noted a drastic decline in the
therapeutic efficacy for old MSCs. In this issue of Stem
Cell Research & Therapy, Zhang and colleagues report
that aged MSCs exhibited higher apoptotic index,
decreased Akt phosphorylation (Thr308), enhanced Bad
activation, and decreased Bax/Bcl-2 ratio. Interestingly,
inhibition of inositol hexakis phosphate kinases (IP6Ks)
using the kinase inhibitor TNP overtly decreased inositolral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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apoptotic index as evidenced by Akt phosphorylation
(Thr308) and Bax/Bcl-2 ratio [1]. IP7, formed by a family
of IP6Ks, represents a physiologic inhibitor of Akt which
mediates survival signal. These authors examined the role
of IP6K inhibition in the therapeutic efficacy of MSCs and
its underlying mechanism. After introduction into an
infarct heart, MSCs prevent deleterious remodeling and
improve cardiac function, although a better understanding
of MSC differentiation in the cardiac scar tissue is still at
large [9]. The beneficial effect of MSCs is believed to be
mediated in part through indirect paracrine actions, thus
recruiting multiple therapeutic growth factors and cyto-
kines to ischemic myocardium [10,11]. However, the over-
all efficacy of stem cell transplantation has been greatly
hampered by several pathological conditions such as
aging, diabetes, and obesity. One of the rather intriguing
findings from Zhang and colleagues is the characterization
of the paracrine profile of MSCs. Their results indicate
that aging negatively modulates the paracrine profile of
MSCs. In particular, overt reductions in the secretion of
angiogenic factors are noted in aged MSCs, especially
under hypoxia. These authors conclude that advanced
aging may impair paracrine efficiency of MSCs at least in
part by IP7 production. Inhibition of IP6K activity inter-
rupts IP7 production and may represent a novel target for
augmenting aged MSC therapeutic efficacy.
It is noteworthy that the overall efficacy of stem cell
transplantation relies on the activity of donor cells and
tissue environment. Novel approaches aiming at revers-
ing dysfunction of transplanted cells or refreshing target
tissues should provide a useful avenue for improvement
of cell therapy efficacy in patients with AMI. The find-
ings reported in this work [1] that inhibition of IP6Ks
turns on Akt signaling, decreases apoptosis, and modu-
lates the paracrine profile in MSCs should shed some
light on a better strategy in promoting the therapeutic
efficacy of MSCs in aging.
Abbreviations
AMI: Acute myocardial infarction; IP6K: Inositol hexakis phosphate kinase;
IP7: Inositol pyrophosphate 7; MSC: Mesenchymal stem cell; Thr308: Threonine
308.
Competing interests
The authors declare that they have no competing interests.
Published:
References
1. Zhang Z, Zhao C, Liang D, Qin X, Li X, Zhang R, Li C, Wang H, Sun D, Cao F:
Inositol pyrophosphates mediate the effects of aging on bone marrow
mesenchymal stem cells by inhibiting Akt signaling. Stem Cell Res Ther
2014, 5:33.
2. Roe M, Messenger J, Weintraub W, Cannon C, Fonarow G, Dai D, Chen A,
Klein L, Masoudi F, McKay C, Hewitt K, Brindis R, Peterson E, Rumsfeld J:
Treatments, trends, and outcomes of acute myocardial infarction and
percutaneous coronary intervention. J Am Coll Cardiol 2010, 56:254–263.
26 Mar 20143. Yeh R, Sidney S, Chandra M, Sorel M, Selby J, Go A: Population trends in
the incidence and outcomes of acute myocardial infarction. N Engl J Med
2010, 362:2155–2165.
4. Chen J, Hsieh A, Dharmarajan K, Masoudi F, Krumholz H: National trends in
heart failure hospitalization after acute myocardial infarction for
medicare beneficiaries: 1998–2010. Circulation 2013, 128:2577–2584.
5. Pittenger M, Martin B: Mesenchymal stem cells and their potential as
cardiac therapeutics. Circ Res 2004, 95:9–20.
6. Dimmeler S, Leri A: Aging and disease as modifiers of efficacy of cell
therapy. Circ Res 2008, 102:1319–1330.
7. Edelberg J, Tang L, Hattori K, Lyden D, Rafii S: Young adult bone marrow-
derived endothelial precursor cells restore aging-impaired cardiac angio-
genic function. Circ Res 2002, 90:E89–E93.
8. Liang H, Hou H, Yi W, Yang G, Gu C, Lau W, Gao E, Ma X, Lu Z, Wei X, Pei J,
Yi D: Increased expression of pigment epithelium-derived factor in aged
mesenchymal stem cells impairs their therapeutic efficacy for attenuat-
ing myocardial infarction injury. Eur Heart J 2013, 34:1681–1690.
9. Psaltis P, Zannettino A, Worthley S, Gronthos S: Concise review:
mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells
2008, 26:2201–2210.
10. Gnecchi M, Zhang Z, Ni A, Dzau V: Paracrine mechanisms in adult stem
cell signaling and therapy. Circ Res 2008, 103:1204–1219.
11. Salem H, Thiemermann C: Mesenchymal stromal cells - current under-
standing and clinical status. Stem Cells 2010, 28:585–596.
Cite this article as: Wang and Ren: Aging as an essential modifier for the
efficacy in mesenchymal stem cell therapy through an inositol phosphate 6
kinase-inositol pyrophosphate 7-dependent mechanism. Stem Cell Research &
Therapy
10.1186/scrt432
2014, 5:43
